Novel therapies for Helicobacter pylori infection

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 1, 1999, Pages 35-42

  Opekun, A R ^a   El Zaimaity, H M T ^a   Osato, M S ^a   Gilger, M A ^a   Malaty, H M ^a   Terry, M ^b   Headon, D R ^b   Graham, D Y ^a,c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b AGENNIX INC   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN; LACTOFERRIN; UREA;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; FEMALE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0032911821     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00435.x     Document Type: Article

References (41)

1. 1 Graham DY. Pathogenic mechanisms leading to Helicobacter pylori induced inflammation. Eur J Gastroenterol Hepatol 1992; 4(Suppl. 2): 29-16.
2. 2 Morris A, Nicholson G. Ingestion of Campylobacter pyloriidis causes gastritis and raised gastric pH. Am J Gastroenterol 1987; 82: 192-9.
3. 3 Rauws EA, Langenberg W, Houthoff HJ, Zanen HC, Tytgat GN. Campylobacter pyloridis associated chronic active gastritis. Gastroenterology 1988; 94: 33-40.
4. 4 Labenz J, Blum AL, Jorius I, et al. Intragastric acidity as a predictor of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin. Gut 1995; 37: 39-43.
5. 5 van der Hulst RW, Weel JF, van der Ende A, ten Kate FJ, Dankert J, Tytgat GN. Therpeutic options after failed Helicobacter pylori eradication therapy. Am J Gastroenterol 1996; 91: 2333-7.
6. 6 Hunt RH. Eradication of Helicobacter pylori Infection. Am J Med 1996; 100: 42S-51S.
7. 7 Evans DJ Jr, Evans DG, Kirkpatrick SS, Graham DY. Characterization of the Helicobacter pylori urease and purification of its subunits. Microbial Pathogen 1991; 10: 15-26.
8. 8 Dunn BE, Vakil NB, Schneider BG, et al. Localization of Helicobacter pylori urease and heat shock protein in human gastric biopsies. Infect Immun 1997; 65: 1181-8.
9. 9 Nilius M, Malferteiner P. Helicobacter pylori enzymes. Aliment PharmTher 1996; 10(Suppl. 1): 65-71.
10. 10 Newel DG. Virulence factors of Helicobacterpylori. Scand J Gastroenterol 1991; (Suppl. 187): 31-8.
11. 11 Lee A. New microbial features. Eur J Gastroenterol Hepatol 1995; 7: 303-9.
12. 12 Hessy SJ, Spencer J, Wyatt JI, et al. Bacterial adhesin and disease activity in Helicobacter pylori associated chronic gastritis. Gut 1990; 31: 134-8.
13. 13 Hazell SL, Lee A. Campylobacter pyloridis, urease, hydrogen ion back diffusion, and gastric ulcers. Lancet 1986; 2: 15-17.
14. 14 Visek WJ, Iwert ME, Nelson NS, Rust JH. Some immunologic properties of jackbean urease and its antibody. Arch Biochem Biophys 1967; 122: 95-104.
15. 15 Bitzan MM, Gold BD, Philpott DJ, et al. Inhibition of Helicobacter pylori and Helicobacter mustelae binding to lipid recptors by bovine colostrum. J Infect Dis 1998; 177: 955-61.
16. 16 Greenberg PD, Cello JP. Treatment of severe diarrhea cause by Cryptosporium parvum with oral bovine immunoglobulin concentrate in patients with AIDS. J Acquir Imune Defic Syndr Hum Retrovirol 1996; 13: 348-54.
17. 17 Evans DG, Evans DJ Jr, Moulds JJ, Graham DY. N-acetyl-neuramininyllactose-binding fibrillar hemagluttinin of Campylobacter pylori: a putative colonization factor antigen. Infect Immun 1988; 56: 2896-906.
18. 18 Tzouvelekis LS, Mentis AF, Makris AM, Spiliadis C, Blackwell C, Weir DM. In vivo binding of Helicobacter pylori to human gastric mucin. Infect Immun 1991; 51: 4252-4.
19. 19 Saitoh T, Natomi H, Zhao WL, et al. Infection of glycolipid receptors for Helicobacter pylori by TLC-immunostaining. FEBS Lett 1991; 282: 385-7.
20. 20 Dunn BE, Altmann M, Cambell GP. Adherence of Helicobacter pylori to gastric carcinoma cells. Rev Infect Dis 1991; 13(Suppl. 8): S657-64.
21. 21 Hirmo S, Kelm S, Schauer R, Nilsson B, Wadstrom T. Adhesin of Helicobacter pylori strains to a2,3-linked sialic acids. Glycoconj J 1996 13: 1005-11.
22. 22 Smith DF, Zopf DA, Ginsburg V. Fractionation of sialyl oligosaccharides of human milk by ion-exchange chromatography. Anal Biochem 1978; 85: 602-8.
23. 23 Simon PM, Goode PL, Mobasseri A, Zopf D. Inhibition of Helicobacter pylori binding to epithelial cells by sialic acid-containing oligosaccharides. Infect Immun 1997; 65: 750-7.
24. 24 Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995; 80: 252-67.
25. 25 Bullen JJ. Significance of iron in infection. Rev Inf Dis 1981; 3: 1127-38.
26. 26 Bullen JJ, Roger HJ, Griffiths E. Role of iron in bacterial infection. Curr Topics Microbiol Immunol 1978; 80: 1-35.
27. 27 Bullen JJ, Joyce PR. Abolition of bactericidal function of polymorphs by ferritin-antiferritin complexes. Immunology 1982; 46: 497-505.
28. 28 Bellamy W, Takase M, Wakabayashi H, Kawase K, Tomita M. Antibacterial specturm oflactoferricin B, a potent bactericidal peptide derived from the N-terminal of bovine lactoferrin. J Appl Bacteriol 1992; 73: 472-9.
29. 29 Miehlke S, Reddy R, Osato MS, Ward PP, Conneely OM, Graham DY. Direct activity of recombinant human lactoferrin against Helicobacter pylori. J Clin Microbiol 1996; 34: 2593-4.
30. 30 Arnold RR, Russell JE, Champion WJ, Brewer M, Gauthier JJ. Bactericidal activity of human lactoferrin: differentiation from the stasis of iron deprivatiton. Infect Immun 1982; 35: 792-9.
31. 31 Ward PP, Piddington CS, Cuningham G. A system for production of commecial quantities of human lactoferrin: a broad spectrum natural antibiotic. Bio/Technology 1995; 13: 498-503.
32. 32 Ward PP, Lo JY, Duke M, May GS, Headon DR, Conneely OM. Production of biologically active recombinant human lactoferrin in Asergillus oryzae. Bio/Technology 1992; 10: 784-9.
33. 33 Ward PP, Cunningham GA, Conneelly OM. Commercial production of lacloferrin, a multifunctional iron-binding glycoprotein. Biotech Gen Eng Rev 1991; 14: 303-19.
34. 34 Clayton CL, Pallen MJ, Kleanthous H, Wren BW, Tabaqchali S. Nucleotise sequence of two genes from Helicobacter pylori encoding for urease subunits. Nucleic Acids Res 1990; 18: 362.
35. 35 Graham DY, Klein PD, Evans DG, et al. Simple noninvasive way to test efficacy of drugs in the eradication of Helicobacter pylori infection: the example of combined bismuth subsalicylate and nitrofurantoin. Am J Gastroenterol 1991; 86: 1158-62.
36. 36 El-Zimaity HMT, Graham DY, Al-Assi MT, et al. Interobserver variation in the histopathological assessment of Helicobacter pylori gastritis. Hum Pathol 1996; 27: 35-41.
37. 37 Mitra AK, Mahalanabis D, Ashraf H, Unicomb L, Eeckels R, Tzipori S. Hyper immune cow colostrum reduces diarrhoea due to rotavirus: a double blind, controlled clinical trial. Acta Pediatr 1995; 84: 996-1001.
38. 38 Kelly Cp Pothoulakis C, Vavva F, Castagliuolo I, et al. Survival of anti-Clostridium difficile bovine immunoglobulin concentrate in the human gastrointestinal tract. Antimicrob Agents Chemother 1997; 41: 236-41.
39. 39 Yamazaki N, Yamauchi K, Kawase K, Hayasawa H, Nakao K, Imoto I. Antibacterial effects of lactoferrin and a pepsin-generated lactoferrin peptide against Helicobacter pylori in vitro. J Infect Chemother 1997; 3: 85-9.
40. 40 Mannick EE, Bravo LE, Zarama G, et al. Inducible nitric oxide synthase, nitrotyrosine, and apoptosis in Helicobacter pylori gastritis: effect of antibiotics and antioxidants. Cancer Res 1996; 56: 3238-43.
41. 41 Zala G, Flury R, Wurst J, Meyenberger C, Ammann R, Wirth HP. Omeprazole/amoxicillin: improved eradication of Helicobacter pylori in smokers because of N-acetylcysteine. Schweiz Med Wochenschr 1994; 124: 1391-7.